NovoCure: There Is Still More Upside
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment. Read why I upgrade NVCR stock from buy ...
These Stocks Are Moving the Most Today: ASML, Nvidia, Morgan Stanley, United Airlines, J.B. Hunt, DJT, Novocure, and More
ASML extends losses after cutting sales guidance, Nvidia stock edges higher, and third-quarter earnings at Morgan Stanley top ...
GlobalData on MSN17h
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
FierceBiotech1d
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
MassDevice15h
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
Business Wire2d
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
STAT1d
A controversial approval for Novocure’s device
The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...
NovoCure’s Growth Potential Boosted by FDA Approval and Market Expansion
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
Novocure shares soar 33% as FDA approves lung cancer treatment
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer.
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...